Vofopitant

An NK1 receptor antagonist (Ki = 0.03 nM), selective for NK1 over NK2 and NK3 receptors (IC50s = >10,000 nM for both), 5-HT1A, 5-HT1D, and 5-HT2A receptors (Kis = 501, 251, and 316 nM, respectively), and histamine H1 and H2 receptors (Kis = 316 and 251 nM, respectively), inhibits resiniferatoxin-induced systemic vascular leakage in guinea pigs (ID50 = 0.007 mg/kg), inhibits emetogen-induced retching and vomiting in ferrets at 0.1 mg/kg, increases the number of entries into the open arms of the elevated plus maze in gerbils at 0.3-5 mg/kg and increases the percentage of time spent in the open arms at 5 mg/kg, potentiates citalopram-induced antidepressant-like behavior in the forced swim test in mice at 40 mg/kg but inhibits citalopram-induced anxiety-like behavior in rats and gerbils at 0.63 and 10 mg/kg. Formulation: A solid. InChI: InChI=1S/C21H23F3N6O/c1-31-18-10-9-16(30-20(21(22,23)24)27-28-29-30)12-15(18)13-26-17-8-5-11-25-19(17)14-6-3-2-4-7-14/h2-4,6-7,9-10,12,17,19,25-26H,5,8,11,13H2,1H3/t17-,19-/m0/s1. InChIKey: XILNRORTJVDYRH-HKUYNNGSSA-N. SMILES: COC(C=C1)=C(C=C1N2C(C(F)(F)F)=NN=N2)CN[C@@H]3[C@H](C4=CC=CC=C4)NCCC3